Business Description

Zoetis Inc
NAICS : 325412
SIC : 2834
ISIN : US98978V1035
Share Class Description:
FRA:ZOE: Class ACompare
Compare
Traded in other countries / regions
ZTS.USA0M3Q.UKZ1TS34.BrazilZTS.MexicoZOE.GermanyZOTS.Austria1ZTS.Italy IPO Date
2013-02-08Description
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.29 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 1.41 | |||||
Debt-to-EBITDA | 1.75 | |||||
Interest Coverage | 15.08 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 7.57 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.7 | |||||
3-Year EBITDA Growth Rate | 8.5 | |||||
3-Year EPS without NRI Growth Rate | 8 | |||||
3-Year FCF Growth Rate | 11.5 | |||||
3-Year Book Growth Rate | 3.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 9.09 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.8 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.12 | |||||
9-Day RSI | 51.05 | |||||
14-Day RSI | 48.67 | |||||
3-1 Month Momentum % | -1.31 | |||||
6-1 Month Momentum % | 1.11 | |||||
12-1 Month Momentum % | -10.17 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.75 | |||||
Quick Ratio | 1.08 | |||||
Cash Ratio | 0.58 | |||||
Days Inventory | 332.62 | |||||
Days Sales Outstanding | 52.9 | |||||
Days Payable | 55.66 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.05 | |||||
Dividend Payout Ratio | 0.29 | |||||
3-Year Dividend Growth Rate | 20 | |||||
Forward Dividend Yield % | 1.2 | |||||
5-Year Yield-on-Cost % | 2.85 | |||||
3-Year Average Share Buyback Ratio | 1.7 | |||||
Shareholder Yield % | 3.54 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 70.62 | |||||
Operating Margin % | 36.65 | |||||
Net Margin % | 26.86 | |||||
FCF Margin % | 24.81 | |||||
ROE % | 49.67 | |||||
ROA % | 17.41 | |||||
ROIC % | 24.54 | |||||
3-Year ROIIC % | 24.52 | |||||
ROC (Joel Greenblatt) % | 55.92 | |||||
ROCE % | 27.67 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 30.57 | |||||
Forward PE Ratio | 26.82 | |||||
PE Ratio without NRI | 28.25 | |||||
Shiller PE Ratio | 44.56 | |||||
Price-to-Owner-Earnings | 34.01 | |||||
PEG Ratio | 2.52 | |||||
PS Ratio | 8.22 | |||||
PB Ratio | 15.72 | |||||
Price-to-Tangible-Book | 81.77 | |||||
Price-to-Free-Cash-Flow | 33.06 | |||||
Price-to-Operating-Cash-Flow | 25.73 | |||||
EV-to-EBIT | 23.72 | |||||
EV-to-Forward-EBIT | 22.6 | |||||
EV-to-EBITDA | 20.66 | |||||
EV-to-Forward-EBITDA | 19.61 | |||||
EV-to-Revenue | 8.6 | |||||
EV-to-Forward-Revenue | 8.55 | |||||
EV-to-FCF | 34.66 | |||||
Price-to-GF-Value | 0.82 | |||||
Price-to-Projected-FCF | 2.9 | |||||
Price-to-DCF (Earnings Based) | 1.17 | |||||
Price-to-DCF (FCF Based) | 1.19 | |||||
Price-to-Median-PS-Value | 0.91 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.67 | |||||
Price-to-Graham-Number | 10.12 | |||||
Earnings Yield (Greenblatt) % | 4.22 | |||||
FCF Yield % | 3.07 | |||||
Forward Rate of Return (Yacktman) % | 12.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zoetis Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 8,572.492 | ||
EPS (TTM) (€) | 5.062 | ||
Beta | 0.84 | ||
3-Year Sharpe Ratio | -0.1 | ||
3-Year Sortino Ratio | -0.14 | ||
Volatility % | 21.26 | ||
14-Day RSI | 48.67 | ||
14-Day ATR (€) | 3.637718 | ||
20-Day SMA (€) | 159.436 | ||
12-1 Month Momentum % | -10.17 | ||
52-Week Range (€) | 135.28 - 185 | ||
Shares Outstanding (Mil) | 447.79 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Zoetis Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Zoetis Inc Stock Events
Event | Date | Price (€) | ||
---|---|---|---|---|
No Event Data |
Zoetis Inc Frequently Asked Questions
What is Zoetis Inc(FRA:ZOE)'s stock price today?
The current price of FRA:ZOE is €157.82. The 52 week high of FRA:ZOE is €185.00 and 52 week low is €135.28.
When is next earnings date of Zoetis Inc(FRA:ZOE)?
The next earnings date of Zoetis Inc(FRA:ZOE) is 2025-05-02 Est..
Does Zoetis Inc(FRA:ZOE) pay dividends? If so, how much?
The Dividend Yield %  of Zoetis Inc(FRA:ZOE) is 1.05% (As of Today), Highest Dividend Payout Ratio of Zoetis Inc(FRA:ZOE) was 0.29. The lowest was 0.16. And the median was 0.2. The  Forward Dividend Yield % of Zoetis Inc(FRA:ZOE) is 1.2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |